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Highlights: 
 A RCT of vitamin D supplementation (12000 IU, 24000 IU and 48000 IU) given 
monthly for one year in people aged 70+ years was conducted to test the effect on 
Grip Strength (GS) and Timed-up and Go test (TUG).  
 Older adults with plasma 25hydroxyvitamin D <25 nmol/L at baseline, had lower GS. 
 However, no effect of vitamin D supplementation on GS and TUG was seen in any of 
the treatment groups in older adults. 
 In the absence of a placebo group, we have not excluded benefit from all three doses.  
 
Abstract 
Vitamin D plays a role in muscle function through genomic and non-genomic processes. The 
objective of this RCT was to determine the effect of monthly supplemental vitamin D3 on 
muscle function in 70+ years old adults. Participants (n=379) were randomized to receive, 
12000 IU, 24000 IU or 48000 IU of vitamin D3 monthly for 12 months.  Standardized Hand 
Grip Strength (GS) and Timed-Up and Go (TUG) were measured before and after vitamin D3 
supplementation. Fasting total plasma 25 hydroxyvitamin D (25OHD) and Parathyroid 
Hormone (PTH) concentrations were measured by Liquid Chromatography Tandem Mass 
Spectrometry (LC-MSMS) and immunoassay, respectively. Baseline plasma 25OHD 
concentrations were 41.3 (SD 19.9), 39.5 (SD 20.6), 38.9 (SD 19.7) nmol/L; GS values were 
28.5 (SD 13.4), 28.8 (SD 13.0) and 28.1 (SD 12.1) kg and TUG test values were 10.8 (SD 2.5), 
11.6 (SD 2.9) and 11.9 (SD 3.6) s for the 12000 IU, 24000 IU and 48000 IU dose groups, 
respectively. Baseline plasma 25OHD concentration < 25 nmol/L was associated with lower 
GS (P=0.003). Post-interventional plasma 25OHD concentrations increased to 55.9 (SD 15.6), 
64.6 (SD15.3) and 79.0 (SD 15.1) nmol/L in the 12000 IU, 24000 IU and 48000 IU dose 
groups, respectively and there was a significant dose-related response in post-interventional 
plasma 25OHD concentration (p<0.0001). Post-interventional GS values were 24.1 (SD 10.1), 
26.2 (SD10.6) and 25.7 (SD 9.4) kg and TUG test values were 11.5 (SD 2.6), 12.0 (SD 3.7) 
and 11.9 (SD 3.2) s for 12000 IU, 24000 IU and 48000 IU dose groups, respectively. The 
change (Δ) in GS and TUG from pre to post-intervention was not different between treatment 
groups before and after the adjustment for confounders, suggesting no effect of the 
intervention. Plasma 25OHD concentration was not associated with GS and TUG test after 
supplementation. In conclusion, plasma 25OHD concentration < 25 nmol/L was associated 
with lower GS at baseline. However, monthly vitamin D3 supplementation with 12000 IU, 
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24000 IU and 48000 IU, for 12 months had no effect on muscle function in older adults aged 
70+ years. 
 
Key words: Older adults, Vitamin D supplementation, Muscle function, Grip strength, Timed-
up and go test 
1. Introduction  
Loss of muscle mass and decreased muscle strength are features of ageing, with an annual loss 
of muscle mass of 0.5 – 1.0 % per year after 70 years of age [1] and a 10 - 15% decline in 
muscle strength per decade in older people aged 70-79 years [2]. Decreased muscle mass and 
strength can result in sarcopenia, which is associated with poorer quality of life, loss of 
independence and increased health care costs [3]. Assessment of Hand Grip Strength (GS) and 
Timed-Up and Go (TUG) are the widely used methods to test the muscle strength and identify 
the presence of sarcopenia [4].   
Links between vitamin D status and muscle function have been reported based on mechanistic 
in vitro studies [5], human observational [6, 7, 8, 9, 10, 11], longitudinal [12] and intervention 
studies [13,14]. Some observational [6, 9, 13] and longitudinal [12] studies have reported 
positive associations between serum 25-hydroxyvitamin D (25OHD) concentration and muscle 
function in older adults, whereas other studies did not find an association [11]. These 
conflicting findings may be due to the differences in the characteristics of the population and 
differences in the vitamin D status of the participants. Current evidence suggests that vitamin 
D status is associated with reduced muscle strength, function and physical performance in older 
adults (over 60 years of age) only when serum 25OHD concentration falls below 50 nmol/L 
[15]. The scientific advisory committee on nutrition (SACN) recommended that serum 25OHD 
concentration should be at least  25 nmol/L all year round for optimal bone and muscle health 
[16].   
The findings from vitamin D intervention studies are inconsistent, reflecting the variation in 
characteristics of the study population (e.g. age, gender, baseline vitamin D status), study 
design and nature of the intervention (route, dose, frequency and form of vitamin D 
supplementation). Some studies show the positive effect of vitamin D supplementation on 
muscle function only in older adults whose baseline serum 25OHD concentrations <30 nmol/L 
[17] or <50 nmol/L [15]. 
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Since the plasma concentration and vitamin D supply required for optimal muscle function in 
older adults are not well understood, we undertook a secondary analysis of a 1-year dose-
ranging randomised vitamin D3 supplementation trial,  to evaluate its effects on muscle 
function [18]. 
  
2. Materials and methods  
Vitamin D in older people (VDOP) study was a randomized double-blind interventional trial 
in 379 male and female older adults aged 70 years or older, living in the North-East of England 
(55◦N), which recruited from November 2012 and May 2013. The primary aim of this study 
was to assess the effect of monthly dose of 12000 IU, 24000 IU or 48000 IU (equivalent to 400 
IU, 800 IU or 1600 IU per day) vitamin D3 (Vigantol, Merck Sereno GmbH, Darmstadt 
Germany) on bone mineral density [18]. 
Potential participants were identified through screening of the electronic records of 25 GP 
practices. Exclusion criteria comprised: taking vitamin D supplements at a dose greater than 
400 IU/day or calcium at a dose greater than 500 mg/day, a fragility fracture within the previous 
6 months, treatment with an anti-resorptive or anabolic treatment for osteoporosis in the 
previous three years, a history of renal stones, previous hip replacement or primary 
hyperparathyroidism, hypercalcaemia (albumin adjusted plasma calcium >2.60 mmol/L), 
hypocalcaemia (albumin adjusted plasma calcium < 2.15 mmol/L) or an estimated glomerular 
filtration rate (eGFR) less than 30 ml/min/1.73 m2).  Ethical permission was given by the Tyne 
and Wear Research Ethics Committee (REC,12/NE/0050). All participants provided written 
informed consent. The sponsor, Newcastle upon Tyne NHS Foundation Trust, provided the 
Research and Development approval for the study (Trial registration: EudraCT 2011 – 004890-
10 and ISRCTN 35648481). Further details about participant recruitment are published 
elsewhere [19]. 
2.1 Intervention and study visits 
Participants were randomized to receive one of three doses of vitamin D3, 12000 IU, 24000 IU 
or 48000 IU, monthly for one year. Both participants and investigators were blinded to the 
treatment received. Study visits took place at baseline and thereafter at 3-monthly intervals (5 
in total). Participants were provided with 3-monthly supplies of vitamin D3 at each study visit.  
2.2 Outcome measures 
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GS (kg) in both the right and left hand was measured using a Jamar hand-grip dynamometer 
(Jamar, Bollington, USA). Three measurements were taken, and the mean value was used for 
analysis. The TUG test was performed once and recorded as the time taken in seconds (s) to 
stand from a sitting position in an arm chair and walk 3m distance [20]. GS and TUG were 
measured before and after 1 year of supplementation. Anthropometry, including, height, 
weight, Fat Mass (FM) and Fat-Free Mass (FFM) were measured at three-month intervals. 
Height was measured using a stadiometer and weight, FM and FFM were measured using a 
bioelectrical impedance analyser (Tanita Crop, Tokyo, Japan). Habitual dietary vitamin D 
intake was assessed using a food frequency questionnaire (FFQ) at the screening visit, the 3rd 
and 5th visits.  The vitamin D intake was calculated as the mean value of FFQ data of screening 
visit, the 3rd and the 5th visits.  
2.3 Biochemical analysis 
Overnight fasting venous blood samples were collected from participants at each visit. The 
25OHD2 and 25OHD3 concentrations in plasma were measured by Liquid Chromatography 
Tandem Mass Spectrometry (LC-MSMS), before and after the intervention.  Total 25OHD 
concentration was calculated by summing 25OHD2 and 25OHD3 values. EDTA plasma was 
used for the analysis of PTH by immunoassay (Immulite, Siemens Healthcare Diagnostics Ltd, 
Camberley, UK). Quality assurance of 25OHD and PTH assay were performed as the part of 
vitamin D Quality Assessment Scheme (http://www.deqas.org/) and the National External 
Quality Assessment Scheme (https://ukneqas.org.uk/). Inter assay variations were < 10% and 
< 7% for 25OHD2 and 25OHD3, respectively. 
2.4 Data and statistical analysis  
Baseline data were available for 379 older adults, while 343 older adults completed the 
intervention study. Thus, the total sample of 379 was used for the baseline data analysis, while 
the data from 343 older adults were used to investigate the intervention effects after 12 months. 
Older adults were sub-divided into two groups based on baseline plasma 25OHD concentration 
< 25 nmol/L, which is the cut-off of value of vitamin D used in the UK to indicate an increased 
risk of deficiency [16] and plasma 25OHD concentration < 50 nmol/L, which is the cut-off for 
vitamin D inadequacy used in North America [21], both of which have recently been 
incorporated in to the National Osteoporosis guidelines in the UK [22].  Statistical analysis of 
the data was conducted using SPSS for Windows version 13.0. Kolmogorov-Smirnov test was 
used to evaluate the distribution of the variables and those that were not normally distributed 
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were log transformed prior to the analysis and were near normally distributed after the 
conversion. Primary outcomes for the study were GS and TUG in response to supplementation 
with 12000 IU, 24000 IU and 48000 IU vitamin D3 per month.  
 
Baseline 25OHD, baseline muscle function variables, age, weight, height, FM, FFM and 
vitamin D intake were predetermined as potential confounders.  Multinomial logistic regression 
analysis was used to investigate the association between muscle function at baseline and plasma 
25OHD concentration (based on whether plasma level was above or below two cut-offs: 25 
nmol/L and 50 nmol/L), adjusting for confounders. The ANOVA test was used to test the effect 
of vitamin D supplementation on muscle function, plasma 25OHD and PTH concentrations. 
ANCOVA was used to test for the effect of the treatment on post-intervention variables after 
controlling for potential confounders (age, weight, height, Fat Mass (FM), Fat Free Mass 
(FFM) and vitamin D intake). The Bonferroni test was used for post hoc comparisons. Multiple 
linear regression was used to test potential effect of plasma 25OHD concentration on muscle 
function after supplementation.  A P value <0.05 was considered as significant.  
 
3. Results  
Table 1 presents the participants’ characteristics at baseline, stratified by vitamin D3 
supplementation dose. Baseline values for the main outcome measures, GS, TUG and plasma 
25OHD concentration were similar across the intervention groups as were mean values for the 
main confounders including weight, height, BMI and age indicating that randomization was 
successful. The initial characteristics of the baseline sample (379 participants) and the sample 
of older adults who completed the intervention study (343 participants) were similar (data are 
not shown).
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Table 1 : Participants’ characteristics at baseline by the dose of vitamin D supplementation  
Characteristics  12000 IU 24000 IU 48000 IU 
 n (%) Mean SD n (%) Mean SD n (%) Mean SD 
Age (years) 126 74.6 4.0 125 75.0 4.2 128 75.4 4.4 
   Age (n, % >70 <71.5) 33 (26.2) 31 (24.8) 33 (25.8) 
   Age (n,% > 71.5 < 74) 36 (28.6) 30 (24.6) 28 (21.9) 
   Age (n,% > 74 < 77) 29 (23.0) 33 (26.4) 29 (22.7) 
   Age (n,% > 77) 28 (22.2) 31 (24.8) 38 (29.7) 
    
Gender (n, % males) 126 (54.8) 125 (52.8) 128 (49.2) 
Weight (kg) 126 73.9 11.8 125 77.1 14.0 128 76.1 14.2 
Height (cm) 126 167.4 8.1 125 167.0 9.8 128 167.4 10.0 
Waist (cm) 125 94.5 11.4 125 97.7 14.0 127 97.5 14.3 
Hip (cm) 125 103.9 8.2 125 105.8 9.5 127 105.3 10.5 
BMI1 (kgm-2) 126 26.3 3.6 124 27.5 4.1 127 27.2 4.0 
   <18.5 0 (0.0) 
50 (41.0) 
60 (32.3) 
16 (33.2)  
1 (0.8) 
31 (25.4) 
65 (34.9)  
28 (33.0) 
0 (0.0) 
41 (33.6) 
61(32.8) 
26 (33.8) 
   18.5 – 24.9 
   25.0 – 29.9 
   >30.0 
Body fat % 124 31.9 8.6 125 32.9 7.7 127 32.5 7.8 
GS2 (kg) 126 28.5 13.4 124 28.8 13.0 127 28.1 12.1 
TUG3 (s) 125 10.8 2.5 124 11.6 2.9 127 11.9 3.6 
Plasma 25OHD4 (nmol/L) 126 41.3 19.9 124 39.5 20.6 128 38.9 19.7 
PTH5 (Pg/ml) 126 48.6 25.7 123 47.4 23.3 128 49.9 21.3 
Dietary vitamin D intake (µg/day) 119 3.6 2.0 121 3.6 2.5 123 4.0 3.0 
 
1 Body Mass Index    2 Grip Strength    3 Timed-Up and-Go 4 25-hydroxy vitamin D  5Parathyroid Hormone   
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Table 2 : Multinomial logistic regression analysis1 of relationships between plasma 25OHD concentration, categorized according to SACN and IOM 
cut-offs, and muscle function at baseline 
 Total population (n=379) Males (n=198) Females (n=181) 
Classification  
OR CI P value* OR CI 
p 
value** 
OR 
CI 
P 
value** 
GS (kg)          
     25OHD < 25 nmol/L2 0.339 0.166 – 0.691 0.003 0.333 0.137 – 0.810 0.015 0.251 0.063 – 1.001 0.050 
     25OHD >25 nmol/L Reference   Reference   Reference   
     25OHD <50 nmol/L3 0.990 0.510 – 1.922 0.976 0.588 0.216 – 1.443 0.229 1.870 0.520 – 6.719 0.338 
     25OHD  >50 nmol/L Reference   Reference   Reference   
          
TUG (s)          
     25OHD < 25 nmol/L 0.645 0.388 – 1.070 0.090 0.501 0.229 – 1.093 0.084 0.720 0.358 – 1.446 0.355 
     25OHD >25 nmol/L Reference   Reference   Reference   
     25OHD < 50 nmol/L 0.697 0.424 – 1.147 0.155 0.775 0.386 – 1.543 0.468 0.584 0.273 – 1.250 0.166 
     25OHD  > 50 nmol/L Reference   Reference   Reference   
1To be in the category of higher muscle function based on dichotomisation at the median value    2 SACN  cut-off     3IOM cut-off 
 
* Adjusted for gender, age, body weight, height, fat mass (FM), fat free mass (FFM) and dietary vitamin D intake 
** Adjusted for age, body weight, height, FM, FFM and dietary vitamin D intake
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Table 2 shows the multinomial logistic regression analysis of the relationships between 
baseline plasma 25OHD concentration and muscle function variables according to the cut-offs 
values of plasma 25OHD concentrations from SACN, 2016 (25 nmol/L) and North American 
Institute of Medicien (IOM), 2011 (50 nmol/L). After adjusting for age, body weight, height, 
FM, FFM and vitamin D intake, older adults who had plasma 25OHD concentration < 25 
nmol/L at baseline were significantly (p=0.003) less likely to have GS above the median 
compared with individuals with plasma 25OHD concentration >25 nmol/L. This relationship 
was evident for GS for both males (p= 0.015) and females (p= 0.050). When using the cut-off 
value of 50 nmol/L, there was no relationship between vitamin D status and either GS or TUG 
for all participants and for both gender groups.  
 
After one year of vitamin D supplementation, there were no differences between treatment 
doses for post-intervention GS or TUG. In addition, there were no significant changes in GS 
and TUG from baseline between intervention arms, with and without adjustment for baseline 
values, age, gender, weight, height, FM, FFM and vitamin D intake. Further, subgroup analysis 
of those with a baseline 25OHD concentration < 50 and <25 nmol/L, did not show any 
significant differences between intervention arms in post-intervention GS and TUG, or for 
change in GS and TUG. As expected, there were significant differences between treatment 
arms in post-interventional plasma 25OHD and change in 25OHD concentration. This relation 
was the same for the sub-group analysis in those with baseline plasma 25OHD concentration 
< 50 nmol/L and < 25 nmol/L. After the supplementation, the mean change in plasma 25OHD 
concentration was 14.3 (SD 12.6), 25.3 (SD 18.0) and 40.9 (SD 19.8) nmol/L for the 12000 
IU, 24000 IU and 48000 IU dose group, respectively. There was no significant difference 
between the groups in unadjusted PTH post-intervention, although the decrease in PTH was 
significant larger at the highest dose after correction for confounders. In subgroup analyses, 
change in PTH was significantly different between intervention arms before and after adjusting 
for confounders comparing those with baseline 25OHD concentrations equal to or above with 
those below 50 nmol/L at baseline but this was not the case for the 25 nmol/L cut point (Table 
3).  
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Table 3 : Effect of vitamin D supplementation on post-interventional and change (Δ) in 
muscle function variables, plasma 25OHD concentration and PTH concentration by the 
dose of vitamin D supplementation 
Parameters 12000 IU/month 24000IU/month 48000IU/month p1 p2 
Total sample (n=343) 
Plasma 25OHD3 (nmol/L) (n=113) (n=114) (n=116)   
   Pre-intervention  41.2 (20.3) 39.4 (20.8) 38.5 (19.4) 0.495  
   Post-intervention 55.9 (15.6) 64.6 (15.3) 79.0 (15.1)* <0.0001 <0.0001 
   Change (Δ) in 25OHD 14.3 (12.6) 25.3 (18.0) 40.9 (19.8)* <0.0001 <0.0001 
PTH4 (pg/mL)      
   Pre-intervention  46.8 (23.5) 47.1 (23.9) 50.6 (21.6) 0.443  
   Post-intervention 44.0 (21.3) 44.6 (24.5) 40.1 (18.4) 0.244 0.016 
   Change (Δ) in PTH -2.9 (18.4) -3.1 (18.2) -10.6 (15.4)* <0.0001 0.001 
GS5 (kg)      
   Pre-intervention  27.5 (12.7) 29.4 (13.2) 28.1 (12.2) 0.641  
   Post-intervention 24.7 (10.1) 26.2 (10.6) 25.7 (9.4) 0.692 0.449 
   Change (Δ) in GS -2.8 (11.6) -3.2 (8.1) -2.4 (7.7) 0.820 0.426 
TUG6 (s)      
   Pre-intervention  10.9 (2.5) 11.5 (2.9) 11.8 (3.5) 0.187  
   Post-intervention 11.5 (2.6) 12.0 (3.7) 11.9 (3.2) 0.437 0.713 
   Change (Δ) in TUG 0.56 (2.32) 0.46 (2.77) 0.15 (2.5) 0.773 0.680 
Older adults with baseline 25OHD < 50 nmol/L (n=242) 
Plasma 25OHD (nmol/L) (n=75) (n=83) (n=84)   
   Pre-intervention  30.2 (10.9) 29.1 (10.3) 29.6 (10.6) 0.862  
   Post-intervention 49.7 (11.8) 60.5 (14.8) 76.8 (14.3)* <0.0001 <0.0001 
   Change (Δ) in 25OHD 19.3 (10.0) 31.3 (15.0) 47.4 (15.3)* <0.0001 <0.0001 
PTH (pg/mL)       
   Pre-intervention  49.9 (24.9) 52.9 (24.4) 54.2 (22.0) 0.210  
   Post-intervention 45.7 (21.5) 48.9 (24.5) 41.0 (19.7) 0.137 0.101 
   Change (Δ) in PTH -4.2 (21.1) -4.0 (19.5) -13.4 (15.3)* 0.001 0.002 
GS (kg)      
   Pre-intervention  26.5 (11.8) 29.1 (13.6) 28.3 (12.8) 0.457  
   Post-intervention 23.8 (10.3) 25.5 (10.3) 25.1 (9.3) 0.801 0.403 
   Change (Δ) in GS -2.7 (12.5) -3.6 (8.5) -3.1 (8.4) 0.486 0.889 
TUG (s)      
   Pre-intervention  10.9 (2.3) 11.8 (2.9) 11.8 (3.2) 0.094  
   Post-intervention 11.7 (2.8) 12.3 (3.9) 12.0 (3.5) 0.560 0.630 
   Change (Δ) in TUG 0.74 (2.4) 0.45 (2.8) 0.29 (2.3) 0.512 0.823 
Older adults with baseline 25OHD < 25 nmol/L (n=93) 
Plasma 25OHD (nmol/L) (n=31) (n=30) (n=32)   
   Pre-intervention 19.3 (4.1) 18.2 (4.5) 18.8 (3.9) 0.582  
   Post-intervention 41.9 (10.7) 55.5 (14.7) 73.7 (12.8)* <0.0001 <0.0001 
   Change (Δ) in 25OHD 22.6 (9.3) 37.3 (14.0) 54.9 (12.7)* <0.0001 <0.0001 
PTH (pg/mL)      
   Pre-intervention  61.9 (27.8) 59.5 (19.3) 58.8 (23.2) 0.930  
   Post-intervention 50.4 (20.6 ) 47.7 (16.6) 41.5 (24.1) 0.102 0.143 
   Change (Δ) in PTH -12.2 (25.9) -11.9 (17.4) -17.4 (14.7) 0.470 0.563 
GS (kg)      
   Pre-intervention  25.6 (13.8) 24.1 (9.1) 25.8 (14.2) 0.895  
   Post-intervention 22.3 (11.2) 22.5 (9.0) 22.8 (7.9) 0.903 0.860 
   Change (Δ) in GS -3.3 (16.1) -1.6 (4.8) -3.0 (9.1) 0.814 0.714 
TUG (s)      
   Pre-intervention  11.0 (2.4) 12.8 (3.7) 12.5 (4.1) 0.938  
   Post-intervention 11.9 (2.8) 13.7 (4.1) 12.9 (4.1) 0.798 0.379 
   Change (Δ) in TUG 0.91 (2.6) 0.88 (2.7) 0.38 (2.5) 0.806 0.823 
1 One-way ANOVA followed by Bonferroni test 
2 ANCOVA controlled for baseline values of the variables, age, gender, weight, height, Fat Mass (FM), Fat Free Mass 
(FFM) and vitamin D intake 
3 25-hydroxyvitamin D  4 Parathyroid Hormone 5Grip Strength  6Timed-Up and Go test 
* Significantly different from 12000 IU and 24000 IU groups 
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After supplementation, plasma 25OHD concentration was not significantly associated with 
either GS or TUG. Significant determinants for GS after supplementation were height 
(p<0.0001), gender (p=<0.0001), age (p=0.002), concurrent body weight (p=0.040) and FM 
(p= 0.040). Similarly, the determinants of TUG were age (p<0.0001), height (p < 0.0001), fat 
mass (p=<0.0001), gender (p=0.018) and vitamin D intake (p=0.019) (data are not shown).  
4. Discussion  
4.1 Main findings  
This double-blind, randomized controlled study found that monthly vitamin D3 
supplementation with 12000 IU, 24000 IU and 48000 IU (which corresponds to 400, 600 and 
1200 µg of dietary vitamin D per day) for one year produced significant dose-related increases 
in plasma 25OHD concentration but had no effect on muscle function in older adults. However, 
at baseline, there was an association between plasma 25OHD concentration and GS, with 
significantly lower GS for those with baseline plasma 25OHD concentration <25 nmol/L in 
both males and females. After supplementation, there were no associations between plasma 
25OHD concentration and muscle function. To our knowledge, this is the first dose-ranging 
RCT conducted in the UK, with a large number of free-living older adults, evaluating the effect 
of vitamin D supplementation on muscle function. 
4.2 Comparison with other studies  
In line with our findings, previous RCTs reported that vitamin D supplementation had no 
beneficial effect on muscle function in older adults, irrespective of the dose of vitamin D 
supplements given. A recent study of female adults of long-term care residence aged 65+ years, 
supplemented with the oral dose of 800 IU vitamin D3 daily for 24 months, reported no effect 
of the supplementation on muscle function measured by gait speed and physical performance 
test [23]. Another study that conducted recruiting home-dwelling men and women aged > 70 
years who were randomized to receive one of the oral doses of 24000 IU, 60000 IU or 24000 
IU vitamin D3 with 300 µg of calcifediol monthly for 12 months, reported no improvement in 
lower extremity function measured by short physical performance battery [24]. Hansen et al., 
2015 reported that among postmenopausal women aged 75 years or younger with baseline 
25OHD concentration 14 – 27 ng/mL, (~ 35 – 67.5 nmol/L) and supplemented with an oral 
dose of 800 IU or 50000 IU vitamin D3 twice monthly for one year had no effect on muscle 
function, assessed by the ‘five sit-stand’ test and TUG test [25]. Further, a recent systematic 
review of community-dwelling older adults aged 65+ years showed that bolus injection or oral 
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vitamin D supplementation of dose ranging from 1000 IU – 600,000 IU, given daily or weekly 
for duration ranging from 16 weeks to 20 months, had no effect on GS and TUG test [26]. 
In contrast, some RCTs have shown improvements in muscle function following vitamin D 
supplementation in older adults. A study conducted among residents of nursing homes of 
average age of 89 years, who had been randomized to receive one of four oral dose of vitamin 
D3 supplements (200 IU, 400 IU, 600 IU and 800 IU) or placebo daily for 5 months, showed 
that those receiving the highest dose had the lowest number of falls compared to the other 
groups [27]. Positive effects of oral vitamin D3 supplements on GS and chair rise test were 
reported in a study of postmenopausal women aged 50 – 65 years who received 1000 IU of 
oral vitamin D3 daily for 9 months [28]. A study of ambulatory older adults with the history of 
falls and serum 25OHD < 12 µg/L (~ 30 nmol/L) who received a single intramuscular injection 
of 60000 IU of ergocalciferol reported a beneficial effect on functional performance, reaction 
time and balance but not on muscle strength [29]. Another RCT of ambulatory older adults live 
in a nursing home with a serum 25OHD concentration < 30 ng/mL (~ 75 nmol/L), randomized 
to receive the oral or intramuscular injection of 600000 IU of cholecalciferol for 12 weeks, 
demonstrated an improvement in muscle strength assessed using quadriceps and physical 
performance battery [30]. According to Zhu et al., 2010, among community-dwelling older 
adults aged 70 – 90 years with serum 25OHD concentration < 24 ng/ml (~ 60 nmol/L) 
supplemented with 1000 IU of vitamin D2 daily for 1 year, improved TUG test only among the 
older adults who were the slowest and weakest at the baseline [31]. Similarly, a systematic 
review with a meta-analysis reported that vitamin D supplementation had a positive effect on 
muscle function in older adults whose baseline serum 25OHD concentration was < 25 nmol/L 
[32]. These inconsistent findings are likely attributed to differences in study design including 
cohort characteristics, duration, dosage, formulations, route of vitamin D supplementation and 
the functional outcomes measured.   
To support our finding of an association between GS and plasma 25OHD concentration below 
25 nmol/L at baseline, Wu et al., 2017, reported that the serum 25OHD concentration of 29 – 
33 nmol/L may optimise musculoskeletal health in middle-aged women (36-57 years) [33]. 
Similar to our study Grimaldi et al., 2013, also reported a positive association between serum 
25OHD concentration and GS, but not with other tests of muscle function and suggested that 
this might be related to anatomical site differences in the androgenic effect of vitamin D or to 
differences in vitamin D receptor expression between upper and lower body muscle and 
consequently muscle function [34].  
AC
CE
PT
ED
 M
AN
US
CR
IPT
13 
 
GS loss in our study was much higher than the reported values in previous studies. The annual 
loss of GS among the older people aged 65 - 75 years reported in previous studies ranged from 
0.3 to 1.3 kg [35, 36, 37]. Though the GS is the standard method to assess sarcopenia, 
differences in the equipment and methods used in various studies may have caused variation 
in the measurements, making it difficult to compare between studies [38].  
In this study we found that plasma 25OHD concentration < 25 nmol/L was  associated with a 
lower GS. This finding supports the recommendation of SACN, UK that for the protection of 
musculoskeletal health, serum 25OHD concentration should not fall below 25 nmol/L 
throughout the year [16]. The US Institute of Medicine (IOM) defines the desired range of 
25OHD as 30 - 50 nmol/L and ESFA (European Food Safety Authority; [39]) advises a target 
value of 50 nmol/L for the general population. The US Endocrine Society advises a target range 
of > 50 nmol/L for patient management who are at risk of vitamin D deficiency [40]. In 
addition, Kotlarczyk et. al., 2017 suggested that at least a concentration between 30-40 ng/ml 
(~ 75 – 100 nmol/L) is required for older adults for optimum muscle function [23]. With regards 
to vitamin D supplementation, the American Geriatrics Society [41] and the Endocrine Society 
[40] recommend vitamin D supplementation of 600–1000 IU/day in older adults who are at 
risk of falling. A systematic review of vitamin D supplementation trials also reported a daily 
dose of 700–1000 IU for physical performance and to prevent falls [42]. SACN, 2016 suggests 
that for the adults > 50 years, the beneficial effect of vitamin D supplementation on muscle 
strength and function can be seen among the adults at the mean baseline serum 25OHD 
concentrations ranging between 25 and 66 nmol/L. In our study, none of the intervention 
groups reached a mean post-intervention plasma 25OHD concentration above this range. 
Accordingly, it can be speculated that the dosages used in this study may not have been high 
enough to reduce the negative effects of the ageing process. The absence of a detectable effect 
of supplementation in this study may also be attributed to the fact that only 30% of our 
participants had a 25OHD <25 nmol/l at baseline. However, as a result of lack of a placebo 
group we did not have data on “natural decline” of muscle function of this group, thus we could 
not compare the effect of vitamin D supplementation with that in non-supplemented 
individuals.  
For tissues other than the kidney, total 25OHD may not fully reflect its availability for local 
hydroxylation into 1,25(OH)2D, which is the active metabolite of vitamin D. Although 
1,25(OH)2D  is responsible for the biological action of vitamin D, its systemic concentration 
does not reflect function at the target tissue level [43, 44]. Many vitamin D target tissues, 
AC
CE
PT
ED
 M
AN
US
CR
IPT
14 
 
including the muscle tissue, are known to express the 1,25(OH)2D-producing enzyme 
CYP27A1 for auto- and paracrine functions. Some reports suggest that muscle tissue may be 
capable of internalising vitamin D binding protein bound 25OHD, although it remains to be 
determined whether this is a significant route of cellular supply of 25OHD [8]. To date, no data 
are available to identify whether free 25OHD provides a better prediction of muscle function 
compared to total 25OHD.  
4.3 Limitations, strengths and future studies 
 We used the lowest intervention dose (which corresponds to the current UK dietary 
recommendation) as the reference group but did not include a placebo group in our study design 
as directed by the approving authorities. As a result, we could not establish the effect of three 
doses of vitamin D supplements compared to a placebo group. Further, we only measured 
plasma 25OHD concentration at baseline and after 1-year supplementation. These samples 
were collected early winter to late spring, during which vitamin D status is lower than the year-
round average in non-supplemented individuals. Therefore, the vitamin D status of individuals 
at baseline and post-intervention may have been misclassified as it may not have fully reflected 
the trajectory of vitamin D status throughout the year. Further, this population was not selected 
randomly from the community. They were invited on the basis of screening of pre-specified 
criteria in their electronic health record. Also, there may have been self-selection bias as those 
that expressed an interest to participate in the study may have been more health conscious. In 
addition, the response to vitamin D supplementation and status may have been influenced by 
factors not measured in this study, such as the distribution of type I and type II of muscle fibres, 
genetic factors, habitual physical activity or exercise habits and hormonal factors.  
This study had several strengths. Its large sample size and the number of available 
measurements that could potentially influence muscle force, i.e. those related to body 
composition and size. The use of three different vitamin D doses corresponding to the UK 
Recommended Nutrient Intake (RNI) [16], the US Recommended Dietary Allowances (RDA) 
[21] and the value below the Tolerable Upper Intake Level (TUIL) was a strength of this study. 
We considered the effect of vitamin D supplementation, without an exercise intervention, on 
muscle. Few trials have looked at the potential interaction between exercise and vitamin D, 
although a recent systematic review presented evidence of an additive effect of resistance 
exercise and vitamin D3 supplementation for the improvement of muscle strength in older 
adults, and we would support suggestions that this is an important area for future research [45]. 
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4.4 Conclusions  
At baseline, plasma 25OHD was associated with GS in both male and females, but only below 
the cut-off level of 25 nmol/L. Vitamin D supplementation significantly increased the plasma 
25OHD concentration of older adults in all doses of supplementation. Vitamin D 
supplementation with 12000 IU, 24000 IU and 48000 IU for 12 months had no effect on muscle 
function in adults older than 70 years.  
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